Clinical Trial

The Effect of Vicia Faba Hydrolysate Supplementation on Muscle Strength Recovery

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 20, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
To investigate the effect of Vicia faba protein concentrate, a protein derived from Fava bean extract, on delayed onset muscle soreness (DOMS). Participants receive either 2.4g/day of PeptiStrong® supplement capsules or placebo capsules for 14 days until a strenuous exercise session. For the last 3 days, 2/3 of them stay on the same treatment and 1/3 of them switch from placebo to PeptiStrong®.
Trial Details
NCT Number NCT06837298
Lead Sponsor PepsiCo Global R&D
Conditions Muscle Damage, Muscle
Enrollment 76 participants
Start Date 2025-02-07
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-20